232 related articles for article (PubMed ID: 36310172)
1. Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma.
Hsieh CH; Kuan WH; Chang WL; Kuo IY; Liu H; Shieh DB; Liu H; Tan B; Wang YC
J Biomed Sci; 2022 Oct; 29(1):90. PubMed ID: 36310172
[TBL] [Abstract][Full Text] [Related]
2. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes.
Kuo IY; Huang YL; Lin CY; Lin CH; Chang WL; Lai WW; Wang YC
J Biomed Sci; 2019 Feb; 26(1):20. PubMed ID: 30777052
[TBL] [Abstract][Full Text] [Related]
3. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression.
Kuo IY; Wu CC; Chang JM; Huang YL; Lin CH; Yan JJ; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC
Int J Cancer; 2014 Aug; 135(3):563-73. PubMed ID: 24407731
[TBL] [Abstract][Full Text] [Related]
4. The expression of p-p62 and nuclear Nrf2 in esophageal squamous cell carcinoma and association with radioresistance.
Wang Z; Zhang J; Li M; Kong L; Yu J
Thorac Cancer; 2020 Jan; 11(1):130-139. PubMed ID: 31755241
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Chemoradiotherapy-Driven Cell Plasticity by miR-200 Family Implicates the Therapeutic Response of Esophageal Squamous Cell Carcinoma.
Lee YC; Lin CH; Chang WL; Lin WD; Pan JK; Wang WJ; Su BC; Chung HH; Tsai CH; Lin FC; Wang WC; Lu PJ
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457185
[TBL] [Abstract][Full Text] [Related]
6. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy.
Zhang J; Jiao Q; Kong L; Yu J; Fang A; Li M; Yu J
Thorac Cancer; 2018 Jun; 9(6):726-735. PubMed ID: 29675925
[TBL] [Abstract][Full Text] [Related]
8. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis.
Feng L; Zhao K; Sun L; Yin X; Zhang J; Liu C; Li B
J Transl Med; 2021 Aug; 19(1):367. PubMed ID: 34446045
[TBL] [Abstract][Full Text] [Related]
9. Repurposed pizotifen malate targeting NRF2 exhibits anti-tumor activity through inducing ferroptosis in esophageal squamous cell carcinoma.
He X; Zhou Y; Chen W; Zhao X; Duan L; Zhou H; Li M; Yu Y; Zhao J; Guo Y; Gu H; Jiang Y; Dong Z; Liu K
Oncogene; 2023 Apr; 42(15):1209-1223. PubMed ID: 36841865
[TBL] [Abstract][Full Text] [Related]
10. Polygalacin D suppresses esophageal squamous cell carcinoma growth and metastasis through regulating miR-142-5p/Nrf2 axis.
Xiao S; Liu N; Yang X; Ji G; Li M
Free Radic Biol Med; 2021 Feb; 164():58-75. PubMed ID: 33307164
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor erythroid 2-related factor 2 promotes radioresistance by regulating glutamate-cysteine ligase modifier subunit and its unique immunoinvasive pattern.
Xue Z; Nuerrula Y; Sitiwaerdi Y; Eli M
Biomol Biomed; 2024 May; 24(3):545-559. PubMed ID: 38340316
[TBL] [Abstract][Full Text] [Related]
12. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2.
Zhang Z; Xiong R; Li C; Xu M; Guo M
Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493
[TBL] [Abstract][Full Text] [Related]
13. MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma.
Lin CH; Tsai CH; Yeh CT; Liang JL; Hung WC; Lin FC; Chang WL; Li HY; Yao YC; Hsu TI; Lee YC; Wang YC; Sheu BS; Lai WW; Calkins MJ; Hsiao M; Lu PJ
Oncotarget; 2016 Jun; 7(26):39680-39693. PubMed ID: 27203740
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target.
Ma S; Paiboonrungruan C; Yan T; Williams KP; Major MB; Chen XL
Ann N Y Acad Sci; 2018 Dec; 1434(1):164-172. PubMed ID: 29752726
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.
Zuo J; Zhao M; Fan Z; Liu B; Wang Y; Li Y; Lv P; Xing L; Zhang X; Shen H
Thorac Cancer; 2020 Mar; 11(3):738-747. PubMed ID: 32012470
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Nrf2/HO-1 expression and its correlation with occurrence in esophageal squamous cell carcinoma.
Gao Y; Li M; Wang B; Ma Y
Genes Genomics; 2023 Jun; 45(6):723-739. PubMed ID: 37043130
[TBL] [Abstract][Full Text] [Related]
17. Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients.
Kuo IY; Chang JM; Jiang SS; Chen CH; Chang IS; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC
Int J Med Sci; 2014; 11(8):779-87. PubMed ID: 24936140
[TBL] [Abstract][Full Text] [Related]
18. NRF2/HO-1 axis, BIRC5, and TP53 expression in ESCC and its correlation with clinical pathological characteristics and prognosis.
Gao Y; Wan L; Li M; Wang B; Ma Y
Int J Biol Markers; 2023 Dec; 38(3-4):174-184. PubMed ID: 37312528
[TBL] [Abstract][Full Text] [Related]
19. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.
Zhou XL; Zhu WG; Zhu ZJ; Wang WW; Deng X; Tao WJ; Ji FZ; Tong YS
Oncologist; 2019 Aug; 24(8):e677-e686. PubMed ID: 31040254
[TBL] [Abstract][Full Text] [Related]
20. High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.
Jiang X; Zhou X; Yu X; Chen X; Hu X; Lu J; Zhao H; Cao Q; Gu Y; Yang Y; Jiang W; Jin M
Mod Pathol; 2022 Jul; 35(7):929-937. PubMed ID: 35194221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
